Anacor Pharmaceuticals, Geoffrey Parker: In a recent Form 4 filing with the SEC, M. Geoffrey Parker, Senior Vice President and CFO at Anacor Pharmaceuticals Inc (NASDAQ:ANAC), acquired 80,000 shares of his company’s stock. Although the stock price closed at $12.17 last Friday, Parker only paid $5 per share, in exercise of in-the-money derivative securities. He now owns 85,000 shares directly, worth $1,029,350, 10,000 more shares through the Delaware Charter Guarantee & Trust Company (Trustee FBO Mr. Geoffrey Monroe Parker IRA), and an extra 136,000 through the Geoffrey M Parker and Jill G Parker Revocable Trust (dated 1/27/00; Geoffrey M Parker and Jill Gofen Parker, Trustees).
The firm’s CFO and Senior VP has been consistently betting on its development and buying stock and options for more than 2 years. After the reported transaction, he still holds the option to buy another 101,579 shares at $5, to expire on Nov. 2020.
His acquisition last Friday follows an important announcement made last Tuesday: Anacor’s new drug application for Tavaborole, its candidate for the topical treatment of onychomycosis, has been accepted by the U.S. Food and Drug Administration (FDA). This means that that the application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) V goal date is July 29, 2014.
But not only Parker is bullish on Anacor. Thirteen of the hedge funds we track also hold the company’s stock. The largest “hedgie” bull is Mark Kingdon‘s Kingdon Capital, followed by Broadfin Capital (Kevin Kotler) and Palo Alto Investors (William Leland Edwards).
Disclosure: Javier Hasse holds no position in any stocks mentioned